Volume | 2,453,347 |
|
|||||
News | - | ||||||
Day High | 52.05 | Low High |
|||||
Day Low | 50.35 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
EXACT Sciences Corporation | EXAS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
52.05 | 50.35 | 52.05 | 50.38 | 51.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
30,953 | 2,453,347 | $ 51.08 | $ 125,315,181 | - | 50.35 - 100.77 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:47:52 | 6 | $ 50.60 | USD |
EXACT Sciences (EXAS) Options Flow Summary
EXACT Sciences Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.14B | 181.53M | - | 2.58B | -204.15M | -1.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
EXACT Sciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EXAS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 54.41 | 56.79 | 50.35 | 53.68 | 3,538,305 | -3.93 | -7.22% |
1 Month | 62.84 | 65.00 | 50.35 | 57.36 | 2,918,269 | -12.36 | -19.67% |
3 Months | 59.75 | 79.62 | 50.35 | 62.68 | 2,766,774 | -9.27 | -15.51% |
6 Months | 61.90 | 79.62 | 50.35 | 64.08 | 2,259,041 | -11.42 | -18.45% |
1 Year | 80.32 | 100.77 | 50.35 | 70.67 | 1,894,111 | -29.84 | -37.15% |
3 Years | 95.81 | 133.99 | 29.27 | 67.36 | 1,962,794 | -45.33 | -47.31% |
5 Years | 96.83 | 159.54 | 29.27 | 80.10 | 1,919,646 | -46.35 | -47.87% |
EXACT Sciences Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening. |